Ticagrelor vs Clopidogrel Effect on MFR in CAD Population

Inclusion criteria

• Age ≥ 18 years old
• Stable coronary artery disease on stable medical treatment.
• BMI equal to or less than 30 kg/m2
• No clinically significant abnormalities in baseline laboratory work
• No clinically significant arrhythmias on baseline 12-lead electrocardiogram
• Female subjects must be post-menopausal, surgically sterilized or have negative urine beta human chorionic gonadotropin pregnancy test at initial screening and maintain effective contraceptive methods throughout the trial and for 7 days following the end of dosing treatment.

Exclusion criteria

• Any contraindication against the use of clopidogrel, ticagrelor and/or ASA.
• Oral anticoagulation therapy.
• History of intracranial bleeding.
• Recent or active pathological bleeding, such as peptic ulcer.
• Moderate or severe hepatic impairment.
• History or risk of bradycardia.
• Known second- or third-degree AV block without pacemaker
• Dyspnea (NYHA III/IV), wheezing asthma or COPD.
• Coronary artery bypass graft (CABG) surgery within 90 days prior to screening or at any time after consent.
• Percutaneous coronary intervention (PCI) within 90 days prior to screening or at any time following consent.
• Acute myocardial infarction or acute coronary syndrome within 60 days prior to screening or at any time following consent.
• Any scheduled surgery during the trial period, including dental.
• Concomitant therapy with strong cytochrome CYP 3A inhibitor or inducer.
• Recent use of dipyridamole, dipyridamole-containing medications (e.g. Aggrenox)
• Known hypersensitivity to the investigational drug or any of its components.
• Known hypersensitivity to adenosine.
• Lactose intolerance
• Breastfeeding or pregnancy.
• Claustrophobia or inability to lie still in a supine position
• Unwillingness to provide informed consent